07:00 , Aug 3, 2009 |  BC Week In Review  |  Company News

Alexis Biotech, Immunomedics deal

The companies will cross-license their respective drug development technologies to develop vaccines against cancer and infectious diseases, including melanoma, chronic lymphocytic leukemia (CLL) and AIDS. Alexis will have non-exclusive rights to Immunomedics' Dock-and-Lock (DNL) conjugation...